McKesson Raises Full-Year Earnings Outlook and Announces Precision Medicine Acquisition
McKesson Corporation (NYSE:MCK) has raised its full-year earnings per share guidance by $0.40 to a range of $44.20–$45.00, reflecting expected growth of approximately 13%–17%. The company cited strong first-quarter performance across several segments and is expanding into oncology through the pending acquisition of Precision Medicine Group (PMG). This deal aims to enhance McKesson's capabilities in clinical research by integrating PMG’s operations with existing assets like Sarah Cannon, Ontada, and the U.S. Oncology Network. The acquisition remains subject to regulatory approval but is expected to be both strategically and financially beneficial for McKesson. The company also highlighted growth from its Prescription Technology Solutions segment while noting a decline in profits within its Medical-Surgical business, which will rebrand as Wellverse and may pursue an IPO by the second half of 2027.
Tickers: $MCK
Topics: healthcare M&A oncology pharmaceuticals